ADHD and Conduct Disorder Co-treatment — MRCPsych Paper B MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: A — Offer the usual ADHD medication pathway, with methylphenidate first line
Conduct disorder is not, by itself, a reason to withhold stimulant treatment. NICE recommends treating clinically impairing ADHD in children with coexisting conduct disorder; methylphenidate remains the first-line pharmacological option when medication criteria are met. Conduct problems should also be addressed psychosocially, particularly through parent-training interventions, rather than requiring their resolution before ADHD treatment. Atomoxetine is not uniquely indicated and is generally considered when methylphenidate and lisdexamfetamine are ineffective or not tolerated. Risperidone is not routine monotherapy for ADHD or conduct disorder; specialist advice is required before adding an atypical antipsychotic for persistent pervasive aggression, rages or irritability. Any substance-misuse or diversion risk should be assessed individually rather than inferred as an automatic stimulant contraindication.
Reference: NICE, Antisocial behaviour and conduct disorders in children and young people: recognition and management (CG158), section 1.6 Pharmacological interventions, 2013 (updated 2017), https://www.nice.org.uk/guidance/cg158/chapter/recommendations